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 ABSTRACT 
Eosinophilic gastroenteritis is a rare 
condition of unknown etiology char-
acterized by eosinophilic inﬁltration 
of the bowel. Corticosteroids are the 
mainstay of EG therapy. Although 
rare, steroid-resistant EG could be a 
life-threatening condition with tissue 
destructive evolution. Associations of 
eosinophilic gastroenteritis with sys-
temic lupus erythematosus have rarely 
been reported. In this report we de-
scribe a case of successful IVIG treat-
ment in a patient with systemic lupus 
erythematosus and steroid-refractory 
eosinophilic gastroenteritis.
Introduction 
Eosinophilic gastroenteritis (EG) is 
a rare condition of unknown etiology 
characterised by eosinophilic inﬁltra-
tion of the bowel. Diagnostic criteria 
include demonstration of eosinophilic 
inﬁltration in the bowel wall, absence 
of extraintestinal disease, and exclu-
sion of disorders mimicking a similar 
condition (1). 
Corticosteroids are the mainstay of EG 
therapy. Although rare, steroid-resistant 
EG could be a life-threatening condition 
with tissue destructive evolution (2). 
Associations of eosinophilic gastroen-
teritis with systemic lupus erythema-
tosus (SLE) have rarely been reported 
(3-7) (summarised in Table I). In this 
report we describe a patient with SLE 
who developed a steroid-refractory 
EG. Since intravenous administration 
of high doses of IgG pooled from 
the plasma of healthy donors (im-
mune globulin therapy, also known as 
‘IVIG’) has consistently been shown 
to be a beneﬁcial and safe therapeutic 
strategy for severe manifestations in 
patients with SLE (8-9), we choose to 
treat this patient with IVIG. 
Case report 
A 37-year old woman, with a history of 
idiopathic thrombocytopenic purpura 
and photosensitivity was admitted in 
December 2009 for a sudden occur-
rence of abdominal pain, refractory 
nausea and vomiting. The patient de-
nied taking any drugs or herbal medi-
cines. She had no history of drug al-
lergy, asthma, or allergic rhinitis. 
Laboratory studies revealed a high 
erythrocyte sedimentation rate (ESR) 
(88 mm/1sth) with normal C-reactive 
protein and an eosinophilic count of 
1560 per microliter. A positive antinu-
clear antibody (ANA), a positive anti-
double stranded (ds) DNA antibody 
and hypocomplementemia were also 
observed. CT scan showed nodular and 
irregular thickening of the folds in the 
proximal small bowel, and ascites (Fig. 
1). The patient underwent a diagnostic 
esophagogastroduodenoscopy which 
revealed a normal-appearing esopha-
gus, stomach and duodenum. Biopsies 
were obtained from the edges of the 
gastric mucosa and duodenum. Histo-
logical analysis of haematoxylin and 
eosin staining of parafﬁn-embedded 
sections revealed a prominent eosi-
nophilic inﬁltration mainly involving 
the lamina propria of the duodenum 
(>25 eosinophils per high-power ﬁeld). 
(Fig. 2A). Rapid urease test (Camplyo-
bacter-like organism test) and immu-
nohistochemical stain were negative 
for Helicobacter organisms. The differ-
ential pathological diagnosis included 
Crohn’s disease, allergic gastroenteri-
tis, idiopathic eosinophilic gastroduo-
denitis, drug reaction or parasitic in-
fection. According to ACR criteria (10) 
the patient was diagnosed as having 
SLE with concomitant EG and intrave-
nous methylprednisolone (1 g/day for 
three days) was started, followed by 
oral prednisone (50 mg/day) without 
any signiﬁcant clinical improvement. 
An infusion protocol with IVIG was 
designed and informed consent was ob-
tained from the patient. The patient was 
infused with IVIG (2 g/kg over a 5-day 
period). An improvement in symptoms 
was noticed within 48 hours after re-
ceiving the ﬁrst infusion and remained 
stable throughout the observation peri-
od. Esophagogastroduodenoscopy was 
repeated one month after and duodenal 
biopsies were obtained. Histological 
analysis showed the disappearance of 
eosinophilic inﬁltrates (Fig. 2B). 
This is the ﬁrst report, to our knowl-
edge, of the treatment of EG in SLE 
with IVIG. Although the mechanisms 
of action of IVIG in autoimmune dis-
eases are still not completely clear, a 
considerable body of evidences sug-
Clinical and Experimental Rheumatology 2011; 29: 1018-1020.
1019
CASE REPORTIVIG in SLE-associated eosinophilic gastroenteritis / F. Ciccia et  al.
gest their potential role in autoimmune 
diseases. IVIg might act enhancing 
the catabolism of IgG, blocking Fcγ 
receptor-mediated mechanisms, and 
inhibiting Fas receptor-induced apop-
tosis. In addition, IVIg seem to contain 
anti-DNA idiotypic antibodies, which 
might inﬂuence the idiopathic network 
(8) 
Despite the absence of randomised 
controlled studies of the use of IVIg 
in SLE, IVIg therapy has been shown 
to be effective in the management of 
patients with various manifestations of 
SLE, especially those with thrombocy-
topenia (11), psychosis (12), and pleu-
ral effusions (13). On the basis of these 
ﬁndings, considering the refractoriness 
to steroid treatment and the risks and 
beneﬁts of a 5-day, high-dose IVIg 
treatment, we chose to treat this pa-
tient with IVIg therapy. Treatment with 
IVIG led to a complete remission of all 
disease manifestations with disappear-
ance of eosinophilic inﬁltrates in our 
patient and there was no recurrence for 
up to sixteen weeks after the last infu-
sion. This effect appears to be remark-
able as standard treatment had failed 
in our patient. Considering that IVIg 
treatment in our patients with SLE-as-
sociated EG was safe and effective, we 
conclude that this regimen may be used 
as an addition to conventional therapy.
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eosinophilic inﬁltrates (C). (H&E staining; 40x magniﬁcation).
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